Dr. Andre H. Goy, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 284
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NJ license 25MA07761300 -
Hematology (Internal Medicine) Physician
NJ license 25MA07761300
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hackensack University Medical Center Hackensack, NJ
- Jersey Shore University Medical Center Neptune, NJ
- Jfk University Medical Center Edison, NJ
- Riverview Medical Center Red Bank, NJ
Medical groups
- Regional Cancer Care Associates LLC (151 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 284
- Services billed
- 4,301
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 515 | 266 |
| Established patient office or other outpatient visit, 40-54 minutes | 149 | 71 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 35 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Hackensack, NJ | 108 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Hackensack, NJ | 95 |
| Calquence (acalabrutinib maleate) | 82 |
| Brukinsa (zanubrutinib) | 63 |
| Imbruvica (ibrutinib) | 47 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Hackensack, NJ | 46 |
| Venclexta (venetoclax) | 28 |
| Prednisone Other prescribers in Hackensack, NJ | 23 |
| Pantoprazole Sodium Other prescribers in Hackensack, NJ | 20 |
| Revlimid (lenalidomide) | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $138 in total to this clinician.
| Celgene Corporation | $38.00 |
|---|---|
| Kite Pharma, Inc. | $31.36 |
| AbbVie Inc. | $30.29 |
| Ipsen Biopharmaceuticals, Inc | $19.57 |
| Pfizer Inc. | $18.64 |
| Food and Beverage | $138 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $291,268 in research payments for these studies, mostly to the institutions running them.
- A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naive Mantle Cell Lymphoma
AstraZeneca Pharmaceuticals LP - A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
E.r. Squibb & Sons, L.l.c. · Completed · NCT01650701 - A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2)
Kite Pharma, Inc. - An open-label, multicenter, phase i/ii trial evaluating the safety, efficacy, and pharmacokinetics of escalating doses of mosunetuzumab (BTCT4465A) as a single agent and combined with atezolizumab in patients with rel…
Genentech, Inc. - Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents
AstraZeneca Pharmaceuticals LP - A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Acerta Pharma LLC - An Open label Phase 2 Study of ACP 196 Acalabrutinib in Subjects With Mantle Cell Lymphoma
Acerta Pharma LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.